Apollomics Inc. - Warrant (OQ:APLMW)
Business Focus: N/A
Apr 25, 2024 08:30 am ET
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that its partner in China, Avistone Biotechnology...
Apr 10, 2024 07:00 am ET
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, presented two posters at the 2024 American Association for Cancer Research (AACR) Annual...
Apr 02, 2024 08:00 am ET
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced poster presentations on vebreltinib (APL-101) at the 2024 American Association...
Mar 28, 2024 07:00 am ET
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial...
Mar 26, 2024 08:00 am ET
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that the Company will report full year 2023 financial results on Thursday, March...
Mar 04, 2024 07:00 am ET
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer of...
Feb 07, 2024 07:00 am ET
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics,...
Jan 19, 2024 04:15 pm ET
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Apollomics Inc. (Nasdaq: APLM) (the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that on January 16, 2024, it received a notification (the “Notice”) from The...
Jan 17, 2024 04:30 pm ET
Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference
Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics,...
Jan 03, 2024 07:00 am ET
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced the completion of enrollment in its Phase 3 bridging study...
Jan 02, 2024 04:30 pm ET
Apollomics to Present at the 2024 Biotech Showcase
Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Sanjeev Redkar, Ph.D., Co-Founder and President, will present at the 2024...
Dec 04, 2023 07:00 am ET
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the presentation of...
Nov 29, 2023 07:30 am ET
Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that Guo-Liang Yu, Ph.D.,...
Nov 28, 2023 07:00 am ET
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced a poster presentation of...
Nov 16, 2023 08:30 am ET
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that its partner in China, Avistone...
Oct 31, 2023 08:30 am ET
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the addition of two new cohorts in its...
Oct 26, 2023 08:50 am ET
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced a report by the Veneto Institute of Oncology on the efficacy response of a patient treated with vebreltinib for GBM with PTPRZ-MET fusion, at the European Society of Medical Oncology...
Oct 23, 2023 08:30 am ET
Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%
Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at the European Society of Medical Oncology Congress (ESMO) 2023, being held in Madrid, Spain...
Oct 16, 2023 06:55 pm ET
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that two abstracts detailing...
Sep 28, 2023 04:17 pm ET
Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced its financial results for...
Sep 06, 2023 07:00 am ET
Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that Sanjeev Redkar, Ph.D.,...
Apr 11, 2023 08:30 am ET
Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium
Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that the company’s Co-Founder and President,...
Mar 30, 2023 08:00 am ET
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq
Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the completion of its business...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.